<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993690</url>
  </required_header>
  <id_info>
    <org_study_id>LP-168-CN101</org_study_id>
    <nct_id>NCT04993690</nct_id>
  </id_info>
  <brief_title>A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma</brief_title>
  <official_title>A Phase 1 Open-Label Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of LP-168 in Adult Patients With Relapse or Refractory B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Lupeng Pharmaceutical Company LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Lupeng Pharmaceutical Company LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL&#xD;
      and NHL who have failed or are intolerant to standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes 2 parts: phase 1a (LP-168 monotherapy dose escalation) and phase 1b&#xD;
      (LP-168 dose expansion). In phase 1a, patients will be enrolled using an 3+3 design. The&#xD;
      starting dose of LP-168 in oral tablet form is 100 mg/day (e.g., 100 mg once daily [QD]).&#xD;
      Once the MTD and/or RP2D is identified in phase 1a dose escalation, enrollment will continue&#xD;
      to phase 1b dose expansion. Cycle length will be 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dose Escalation and determination of MTD; multiple dose levels of LP-168 to be evaluated</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase 1a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for Phase2 (RP2D)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase Ia/Ib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of LP-168 by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase Ia/Ib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>To assess the preliminary anti-tumor activity of LP-168 based on overall response rate (ORR) as assessed by investigator and IRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>To assess the preliminary anti-tumor activity of LP-168 based on Progression free survival (PFS) as assessed by the Investigator and IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>To assess the preliminary anti-tumor activity of LP-168 based on Duration of response (DOR) as assessed by the Investigator and IRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) As Assessed By Maximum Observed Plasma Concentration (Cmax) Of LP-168</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Phase Ia/Ib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK As Assessed By Area Under The Plasma Concentration Time Curve From Time 0 To The Time Of The Last Quantifiable Concentration (AUC0-t) Of LP-168</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Phase Ia/Ib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK As Assessed By Time To Maximum Observed Plasma Concentration (Tmax) Of LP-168</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Phase Ia/Ib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK As Assessed By Terminal Half-life (t1/2) Of LP-168</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Phase Ia/Ib</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase I Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and determination of MTD; multiple dose levels of LP-168 to be evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Expansion A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL/SLL patients treated with prior regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Expansion B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL/SLL patients with no prior therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Expansion C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MCL patients treated with prior regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Expansion D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WM patients treated with prior regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Expansion E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MZL patients treated with prior regimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LP-168 tablet</intervention_name>
    <description>Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily</description>
    <arm_group_label>Phase I Dose Escalation</arm_group_label>
    <arm_group_label>Phase I Dose Expansion A</arm_group_label>
    <arm_group_label>Phase I Dose Expansion B</arm_group_label>
    <arm_group_label>Phase I Dose Expansion C</arm_group_label>
    <arm_group_label>Phase I Dose Expansion D</arm_group_label>
    <arm_group_label>Phase I Dose Expansion E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Per 2017 revised WHO lymphoma classification criteria, subject must have either:&#xD;
&#xD;
        Diagnosed with relapsed or refractory DLBCL or FL and require treatment in the opinion of&#xD;
        the Investigator and have received 2 lines SOC.&#xD;
&#xD;
        Diagnosed with relapsed or refractory non-Hodgkin's lymphoma associated with B-cell&#xD;
        proliferation (such as CLL\ SLL \ MCL \ MZL \ WM, etc.) in need of treatment in the opinion&#xD;
        of the Investigator and have received 1 line SOC.&#xD;
&#xD;
          -  Adequate hematologic function.&#xD;
&#xD;
          -  Adequate hepatic and renal function.&#xD;
&#xD;
          -  Ability to receive study drug therapy orally and willing to receive examinations.&#xD;
&#xD;
          -  Willingness of men and women of reproductive potential (defined as following menarche&#xD;
             and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically&#xD;
             sterile) to observe conventional and effective birth control.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  According to the 2017 revised WHO Lymphoma Classification Criteria, patients diagnosed&#xD;
             with the following diseases: Burkitt lymphoma or Burkitt-like lymphoma, lymphoblastic&#xD;
             lymphoma/leukemia, and post-transplant lymphoproliferative disease(PTLD).&#xD;
&#xD;
          -  Prior malignancy (other than the disease under study) within the past 3 years, except&#xD;
             for curatively treated basal or squamous cell skin cancer, carcinoma in situ of the&#xD;
             cervix or breast cancer.&#xD;
&#xD;
          -  Subjects who have received the following treatments within 4 weeks or 5 half-lives&#xD;
             before the first dose of LP-168:&#xD;
&#xD;
        Antitumor therapies including myelosuppressive chemotherapy, targeted therapy, biological&#xD;
        therapy and/or immunotherapy; Any investigational treatment; Patients who have undergone&#xD;
        major surgery, severe trauma or radiotherapy.&#xD;
&#xD;
          -  Subjects who have received the following treatments within 2 weeks before the first&#xD;
             dose of LP-168:&#xD;
&#xD;
        Steroids or traditional herbal medicine for antitumor purposes; Strong and moderate CYP3A&#xD;
        inhibitors and inducers; All drugs that may cause QTc interval prolongation or torsional&#xD;
        tachycardia.&#xD;
&#xD;
          -  Disease states where clinical manifestations may be difficult to control, including&#xD;
             HIV, HBV, HCV, syphilis positive or active bacterial and fungal infections; Disease&#xD;
             affects the central nervous system with obvious symptoms; Autoimmune hemolytic anemia&#xD;
             or Idiopathic thrombocytopenic purpura. Any gastrointestinal conditions that may&#xD;
             severely affect the study drug absorption or pharmacokinetic parameters.&#xD;
&#xD;
          -  Subjects who cannot tolerate urine collection, venipuncture, lymph node biopsy, and&#xD;
             bone marrow aspiration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Zhu, MD, PhD</last_name>
    <phone>+86-010-88196596</phone>
    <email>zj@bjcancer.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuqin Song, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jun Zhu</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu</last_name>
      <phone>+861088196596</phone>
      <email>zj@bjcancer.org</email>
    </contact>
    <contact_backup>
      <last_name>Yuqin Song</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

